Abstract: Anemia is a common complication of chronic kidney disease (CKD). There are various causes of renal anemia such as decreased production of erythropoietin, resistance to erythropoietin, shortened survival of red blood cells, and bone marrow fibrosis. Secondary hyperparathyroidism (SHPT) is a less recognized, but potentially significant cause of renal anemia in CKD patients. Parathyroid hormone (PTH) has been regarded as a uremic toxin that has multiple adverse effects, and its elevated levels have been associated with renal anemia in hemodialysis patients. Moreover, recent clinical studies have shown that the treatment of SHPT using either vitamin D receptor activators, calcimimetics, or parathyroidectomy leads to improvement of anemia, supporting the role of PTH in renal anemia. Emerging data have also indicated the involvement of bone-derived fibroblast growth factor 23 in renal anemia. This review summarizes recent insights into the role of PTH in renal anemia and discusses the importance of treating SHPT in improving the control of renal anemia in hemodialysis patients.
Anemia is a common complication of chronic kidney disease (CKD) (1) . There are various causes of renal anemia such as decreased production of erythropoietin (EPO), resistance to EPO, shortened survival of red blood cells (RBCs), and bone marrow fibrosis. Secondary hyperparathyroidism (SHPT) is a less recognized, but potentially significant cause of renal anemia in CKD patients. Parathyroid hormone (PTH) has been regarded as a uremic toxin that potentially inhibits EPO synthesis, shortens the survival of RBCs, and causes myelofibrosis and thereby decreases hematopoiesis (2) (3) (4) (5) (6) (7) (8) .
Observational studies have shown a link between SHPT and renal anemia and recent clinical studies have shown that the treatment of SHPT using either vitamin D receptor activators (VDRAs), calcimimetics, or parathyroidectomy (PTx) leads to improvement of anemia. Furthermore, emerging data have indicated that fibroblast growth factor 23 (FGF23), a bone-derived circulating hormone that plays a crucial role in phosphate and vitamin D metabolism (9) (10) (11) (12) , is also involved in ineffective erythropoiesis in CKD (13) (14) (15) .
In this review, we summarize recent insights into the role of PTH in renal anemia and discuss the importance of treating SHPT in improving the control of renal anemia in hemodialysis patients.
PATHOGENESIS OF RENAL ANEMIA ASSOCIATED WITH SHPT
Bone marrow fibrosis Studies have provided evidence suggesting that SHPT plays crucial roles in renal anemia, which is mediated via multiple pathways (2) . The classical theory was that excess secretion of PTH leads to bone marrow fibrosis and consequent interference with erythropoiesis. This possibility was first raised by Rao et al., who demonstrated that patients with a poor response to EPO had higher percentages of osteoclastic and eroded bone surfaces and greater degree of marrow fibrosis in association with higher PTH levels compared to those with a good response (3). This finding indicates that the severity of SHPT and the extent of bone marrow fibrosis increase the dose of EPO needed to achieve an adequate hematocrit response.
Inhibition of EPO synthesis
Several studies have also suggested that SHPT affects endogenous EPO synthesis. Although ESRD patients undergoing dialysis have little, if any, kidney function, they may still have preserved function to synthesize EPO. Two independent groups evaluated the effect of surgical PTx, the definitive therapy for refractory SHPT, and consistently demonstrated a significant increase in circulating EPO levels after PTx (4, 5) . These findings suggest that high PTH levels suppress the endogenous EPO synthesis and thereby contribute to renal anemia, although the molecular mechanisms through which PTH negatively regulates EPO synthesis are mostly unknown.
Inhibition of bone marrow erythroid progenitors
An early study by Meytes et al. showed that PTH in concentrations comparable to those found in the blood of uremic patients produces a marked inhibition of mouse bone marrow burst-forming unitserythroid (BFU-E) and increasing the concentration of EPO overcomes this action of PTH (6) . However, these results have not been reproduced by other groups (16) (17) (18) , leaving it unclear whether PTH inhibits erythropoiesis in renal failure.
Shortened RBC survival
The effect of PTH on RBC osmotic fragility was examined by Bogin et al. (7) . They demonstrated that PTH increases the osmotic fragility of RBC through enhanced calcium entry into RBC. A subsequent study by Akmal et al. further showed that 51 Cr-labeled RBC survival was shortened in 5/6 nephrectomized dogs, but the reduced RBC survival was attenuated and normalized in uremic dogs with parathyroidectomy (8) . These data suggest that PTH is among the factors responsible for the shortened RBC survival in renal failure.
Elevated FGF23 levels
The principal role of FGF23 is to induce urinary phosphate excretion, suppresses 1,25-dihydroxyvitamin D (1, 25 [OH] 2 D) production, and inhibit PTH secretion through binding to the Klotho-FGFR1 complex (9-11). However, accumulating evidence has suggested detrimental effects of FGF23 on non-target organs in a Klothoindependent manner (12). Coe et al. have shown that FGF23 negatively regulates erythropoiesis through suppression of EPO production and EPO receptor expression (13) . Furthermore, a recent experimental study by Singh has demonstrated that FGF23 directly targets hepatocytes to promote inflammation (14) . Because chronic inflammation is a common cause of anemia, the FGF23-induced inflammation may also contribute to the renal anemia and hyporesponsiveness to EPO. Supporting these experimental findings, a recent report from the Chronic Renal Insufficiency Cohort Study (CRIC) demonstrated significant associations of elevated FGF23 levels with prevalent anemia, change in hemoglobin over time, and development of anemia (15) .
CLINICAL STUDIES LINKING RENAL
ANEMIA AND SHPT
High PTH levels
The possible roles of PTH in renal anemia have been supported by a number of clinical observations. Several observational studies have examined the association between PTH levels and renal anemia. Kalantar-Zadeh et al. analyzed the national database of a large dialysis organization and showed that higher PTH levels were independently associated with ESA hyporesponsiveness (19) . Similarly, in another cohort of hemodialysis patients, Gaweda et al. reported a modest but significant association between higher PTH levels and decreased erythropoietic response (20) .
Parathyroidectomy
PTx is the most drastic treatment for SHPT, and early studies have focused on the effect of PTx on EPO doses or hemoglobin levels to explore the role of PTH in renal anemia (21) (22) (23) (24) (25) (26) . One of the most representative studies was conducted by Trunzo et al. (26) . The researchers analyzed data from 37 ESRD patients who underwent PTx for severe SHPT and found that PTx led to a profound decrease in EPO doses with hemoglobin levels being an upward trend. Similar findings have been reported by multiple independent groups, and these highly consistent results may suggest a substantial beneficial effect of PTx on renal anemia.
Calcimimetics
Calcimimetic cinacalcet hydrochloride is the most recent option for the treatment of SHPT (27) . This agent allosterically modulates the parathyroid calcium-sensing receptor (CaSR) and increases its sensitivity to extracellular calcium, thereby decreasing PTH synthesis and secretion (28) . Since the introduction of cinacalcet, several small-scale studies examined the impact of cinacalcet on renal anemia (29, 30) . These studies reported an increase in hemoglobin levels or a reduction in the doses of erythropoiesis-stimulating agents (ESA) following the use of cinacalcet for SHPT.
To further validate these preliminary findings, we analyzed data from the MBD-5D, a multicenter, prospective observational study of Japanese hemodialysis patients with SHPT (31). We defined the primary outcome measure as the achievement of a hemoglobin level ≥ 10.0 g/dL. Among 3201 cinacalcet-naïve individuals at baseline, cinacalcet was initiated in 1337 individuals during the follow up. After adjusting for potential confounders, we found that each additional 6-month duration on cinacalcet was associated with a 1.1-fold increase in the odds of achieving the target hemoglobin level.
There are several possible mechanisms through that cinacalcet could improve renal anemia. The most plausible mechanism is that decreased PTH levels by cinacalcet attenuate the multiple inhibitory effects of PTH on erythropoiesis. In addition, because cinacalcet also inhibits FGF23 secretion (32, 33) , cinacalcet-induced reduction in FGF23 levels may contribute to improved renal anemia. Furthermore, it should be noted that the CaSR is also expressed in hematopoietic stem cells and has a function in retaining these cells in close physical proximity to the endosteal surface of the bone marrow and the regulatory niche components (34). Thus, it is possible the allosteric action of cinacalcet on CaSR enhances the lodging of hematopoietic stem cells in the endosteal niche and thereby facilitates erythropoiesis.
Vitamin D
Treatment with VDRAs, such as calcitriol and maxacalcitol, has long been the primary strategy for the management of SHPT. Several nonrandomized studies examined the effect of VDRAs on renal anemia and demonstrated a reduction in EPO doses or improved hemoglobin levels among patients treated with VDRAs (35) (36) (37) (40) . The investigators demonstrated that 6 months of supplementation with ergocalciferol increased serum 25(OH)D levels, but had no effect on EPO dose. These findings indicate that nutritional vitamin D has no role to play in the management of anemia in hemodialysis patients. It remains, however, unknown whether systemically administered VDRAs directly affect erythropoiesis independently of the effect on PTH. Further research is required to evaluate this possibility.
CONCLUSIONS
This review summarizes recent experimental and clinical data suggesting the role of PTH in renal anemia. Accumulating evidence supports the causal role of PTH in renal anemia and provide additional rationale for controlling PTH secretion in ESRD patients. Future clinical trials should determine the effect of PTH-lowering therapy on hemoglobin levels or ESA doses as a primary endpoint.
